Rhythm Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-02-01

Employees: 226

Market Cap: -

Website: http://www.rhythmtx.com

Introduction: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Clinical Trials

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Phase 2

Completed

Conditions: Genetic Obesity
Obesity
Obesity Due to Melanocortin 4 Receptor Deficiency

Interventions: Drug: Setmelanotide

First Posted Date: 2017-01-06

Last Posted Date: 2023-08-18

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 213

Registration Number: NCT03013543

Locations: 🇺🇸
AXIS South Florida Clinical Trials, Hialeah, Florida, United States
🇺🇸
Synexus Clinical Research US, Inc. - Akron, Akron, Ohio, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 54 locations

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

Phase 3

Completed

Conditions: Pro-opiomelanocortin (POMC) Deficiency Obesity

Interventions: Drug: Setmelanotide
Drug: Placebo

First Posted Date: 2016-09-12

Last Posted Date: 2023-09-21

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT02896192

Locations: 🇩🇪
Charité Campus Virchow-Klinikum / Institute for Experimental Pediatric Endocrinology, Berlin, Germany
🇬🇧
University of Cambridge Metabolic Research Laboratories, Cambridge, United Kingdom
🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States

and more 4 locations

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

Completed

Conditions: Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

First Posted Date: 2016-07-29

Last Posted Date: 2022-11-15

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 5966

Registration Number: NCT02849977

Locations: 🇺🇸
Axis Clinical Trails, Los Angeles, California, United States
🇺🇸
PRI, LLC - Newport Beach - M3 Wake Research, Newport Beach, California, United States
🇺🇸
South Florida Clinical Trials, Hialeah, Florida, United States

and more 54 locations

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

Phase 1

Completed

Conditions: Obese
Overweight

Interventions: Drug: Placebo
Drug: RM-493

First Posted Date: 2015-05-01

Last Posted Date: 2015-05-01

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 57

Registration Number: NCT02431442

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Phase 2

Completed

Conditions: Prader-Willi Syndrome

Interventions: Drug: Setmelanotide
Drug: Placebo

First Posted Date: 2014-12-08

Last Posted Date: 2023-07-27

Lead Sponsor: Rhythm Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT02311673

Locations: 🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States
🇺🇸
Winthrop University Hospital, Mineola, New York, United States
🇺🇸
University of California Irvine, Irvine, California, United States

and more 2 locations